No Data
No Data
Cisen Pharmaceutical's sales volume of the winning varieties in the centralized procurement has increased significantly. It is predicted that the sales of the large infusion sector will trend towards stability in the second half of the year. | Live from t
①At the earnings conference, the director of Cisen Pharmaceutical, Xu Xinbing, explained the gross margin and revenue decline of the company in the first half of the year. ②Xu Xinbing said that the company's sales volume of four varieties that were awarded in the eighth batch of centralized procurement showed a significant year-on-year increase. ③Du Zhenxin, the chairman of the company, introduced the company's development of generic drugs and innovative drugs.
Chenxin Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Chenxin Pharmaceutical Co., Ltd.
Cisen Pharmaceutical (603367.SH): net income of 0.27 billion yuan in the first half of the year, a year-on-year increase of 2.33%.
On August 27th, Gelonhui, Cisen Pharmaceutical (603367.SH) announced its semi-annual report. In the first half of 2024, the company achieved a revenue of 2.071 billion yuan, a decrease of 6.72% compared to the same period last year. The company's total profit amounted to 0.292 billion yuan, an increase of 0.34% compared to the same period last year. The net income attributable to the owner of the parent company was 0.27 billion yuan, an increase of 2.33% compared to the same period last year. A cash dividend of 2.20 yuan per 10 shares was distributed to all shareholders.
Cisen Pharmaceutical (603367.SH) plans to distribute a dividend of 0.436 yuan per share on June 27th.
Cisen Pharmaceutical (603367.SH) announced that it plans to distribute annual equity dividends in 2023: A shares will receive cash dividends of... per share.
Is Cisen Pharmaceutical (SHSE:603367) Using Too Much Debt?
No Data